Details werden geladen...
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer | The Manila Times
First patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney.OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA2 study which recently completed patient enrollment.TLX597-Tx is Telix’s next generation PSMA3-targeting small molecule radioligand therapy candidate designed to improve efficacy and quality of life in earlier-stage prostate cancer. MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) and St Vincent’s Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent’s Hospital in Sydney, Australia.
Ähnliche Seiten
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study - The Economic Times
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/johnson-johnson-prostate-cancer-drug-reduces-risk-of-cancer-spread-and-death-in-late-stage-study/articleshow/131422780.cms
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer | The Manila Times
https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/pluvicto-demonstrated-consistent-efficacy-across-key-patient-subgroups-in-metastatic-hormone-sensitive-prostate-cancer/2355120
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo | The Manila Times
https://www.manilatimes.net/2026/07/09/tmt-newswire/pr-newswire/lynk-pharmaceuticals-announces-first-patient-dosed-in-phase-ii-clinical-trial-of-lnk01004-ointment-for-vitiligo/2381288Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus | The Manila Times
https://www.manilatimes.net/2026/07/14/tmt-newswire/globenewswire/atea-pharmaceuticals-initiates-first-in-human-phase-1-clinical-trial-of-at-587-for-the-treatment-of-hepatitis-e-virus/2383989IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/pr-newswire/ipax-2-study-of-tlx101-tx-in-first-line-glioblastoma-completes-enrolment-and-confirms-dosing/2346661